New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
06:09 EDTTTHI, LLYTransition Therapeutics begins Phase 2 study of diabetes candidate TT-401
Transition Therapeutics (TTHI) dosed the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly (LLY). The objectives of the study will be to evaluate the safety and effectiveness of TT-401 compared to once-weekly exenatide extended release and placebo.
News For TTHI;LLY From The Last 14 Days
Check below for free stories on TTHI;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information
July 16, 2014
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Subscribe for More Information
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
July 15, 2014
11:13 EDTLLYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTTTHIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTLLYAnthera Pharmaceuticals to host conference call
Management discusses the acquisition of Sollpura (liprotamase) for Exocrine Pancreatic Insufficiency from Eli Lilly & Company on a conference call to be held on July 15 at 8:30 am.
07:35 EDTLLYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
07:01 EDTTTHITransition Therapeutics initiated with a Buy at H.C. Wainwright
Subscribe for More Information
05:47 EDTLLYEli Lilly announces results from five datasets from Alzheimer's disease study
Eli Lilly announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease. Analysis findings demonstrate that cognitive deficits predict subsequent functional deficits and suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. These data were presented today at the Alzheimer's Association International Conference 2014 in Copenhagen, Denmark as part of the featured research session, "Statistics in the Race against Alzheimer's Disease." Hong Liu-Seifert, Ph.D., study research advisor at Eli Lilly stated, "These data support the concept that decline in cognition is later reflected in changes in function. This suggests that with treatments that target the underlying neuropathology of disease, effects on function may take longer to observe in clinical studies. Currently available scales were not developed to assess subtle functional changes or treatment effects on these deficits in patients with early or mild Alzheimer's disease, and there is debate as to how much variability exists in these scales globally. Therefore, we support discussion of alternative ways to demonstrate clinical meaningfulness in early or mild Alzheimer's disease."
July 14, 2014
16:45 EDTLLYAnthera Pharmaceuticals acquires Sollpura from Eli Lilly
Subscribe for More Information
07:23 EDTLLYAlzheimer's Association to hold a conference
Subscribe for More Information
July 13, 2014
13:11 EDTLLYLilly study finds combination therapy better in removing amyloid-beta protein
Subscribe for More Information
July 11, 2014
06:02 EDTTTHITransition Therapeutics appoints Carl Damiani as COO
Transition Therapeutics announced that Carl Damiani has been appointed to the role of COO of Transition. Since joining Transition in 2003, Damiani has held the roles of vice-president of Business Development and Director of Business Development.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use